TY - JOUR
T1 - Different oxysterols have opposing actions at N-methyl-d-aspartate receptors
AU - Linsenbardt, Andrew J.
AU - Taylor, Amanda
AU - Emnett, Christine M.
AU - Doherty, James J.
AU - Krishnan, Kathiresan
AU - Covey, Douglas F.
AU - Paul, Steven M.
AU - Zorumski, Charles F.
AU - Mennerick, Steven
N1 - Funding Information:
The authors thank Ann Benz for technical help with cultures. The authors also thank laboratory members, Gustav Akk and Larry Eisenman for discussion. This work was supported by National Institutes of Health Grants MH078823 , MH077791 , AA017413 , GM47969, T32 DA007261 , and the Bantly Foundation . Washington University receives income and equity based on a license of related technology to Sage Therapeutics, Inc. D.F.C. and C.F.Z. and have equity holdings in Sage Therapeutics, Inc. Sage Therapeutics, Inc. did not support this research or have any other role in the research or its conclusions.
PY - 2014/10
Y1 - 2014/10
N2 - Oxysterols have emerged as important biomarkers in disease and as signaling molecules. We recently showed that the oxysterol 24(S)-hydroxycholesterol, the major brain cholesterol metabolite, potently and selectively enhances NMDA receptor function at a site distinct from other modulators. Here we further characterize the pharmacological mechanisms of 24(S)-hydroxycholesterol and its synthetic analog SGE201. We describe an oxysterol antagonist of this positive allosteric modulation, 25-hydroxycholesterol. We found that 24(S)- hydroxycholesterol and SGE201 primarily increased the efficacy of NMDAR agonists but did not directly gate the channel or increase functional receptor number. Rather than binding to a direct aqueous-accessible site, oxysterols may partition into the plasma membrane to access the NMDAR, likely explaining slow onset and offset kinetics of modulation. Interestingly, oxysterols were ineffective when applied to the cytosolic face of inside-out membrane patches or through a whole-cell pipette solution, suggesting a non-intracellular site. We also found that another natural oxysterol, 25-hydroxycholesterol, although exhibiting slight potentiation on its own, non-competitively and enantioselectively antagonized the effects of 24(S)-hydroxycholesterol analogs. In summary, we suggest two novel allosteric sites on NMDARs that separately modulate channel gating, but together oppose each other.
AB - Oxysterols have emerged as important biomarkers in disease and as signaling molecules. We recently showed that the oxysterol 24(S)-hydroxycholesterol, the major brain cholesterol metabolite, potently and selectively enhances NMDA receptor function at a site distinct from other modulators. Here we further characterize the pharmacological mechanisms of 24(S)-hydroxycholesterol and its synthetic analog SGE201. We describe an oxysterol antagonist of this positive allosteric modulation, 25-hydroxycholesterol. We found that 24(S)- hydroxycholesterol and SGE201 primarily increased the efficacy of NMDAR agonists but did not directly gate the channel or increase functional receptor number. Rather than binding to a direct aqueous-accessible site, oxysterols may partition into the plasma membrane to access the NMDAR, likely explaining slow onset and offset kinetics of modulation. Interestingly, oxysterols were ineffective when applied to the cytosolic face of inside-out membrane patches or through a whole-cell pipette solution, suggesting a non-intracellular site. We also found that another natural oxysterol, 25-hydroxycholesterol, although exhibiting slight potentiation on its own, non-competitively and enantioselectively antagonized the effects of 24(S)-hydroxycholesterol analogs. In summary, we suggest two novel allosteric sites on NMDARs that separately modulate channel gating, but together oppose each other.
KW - Allosteric
KW - Gating
KW - Modulation
KW - NMDA receptor
KW - Neurodegeneration
UR - http://www.scopus.com/inward/record.url?scp=84902492052&partnerID=8YFLogxK
U2 - 10.1016/j.neuropharm.2014.05.027
DO - 10.1016/j.neuropharm.2014.05.027
M3 - Article
C2 - 24878244
AN - SCOPUS:84902492052
SN - 0028-3908
VL - 85
SP - 232
EP - 242
JO - Neuropharmacology
JF - Neuropharmacology
ER -